Climb Bio Inc (CLYM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $608.53M
Last updated: Nov 17, 2026 at 11:04 AM ET
Climb Bio Inc (CLYM) Stock Forecast
Analysts expect Climb Bio (CLYM) to earn -$0.75 per share in the fiscal year ending Dec 31, 2026. Of 16 analysts, 16 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 16 ratings average 1.88, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 12.5% |
| Buy | 14 | 87.5% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 16
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$0.75
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.99
- EPS consensus, revenue $576920
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.75 | -$0.77 to -$0.74 | 9 | N/A | N/A | 15 |
| Dec 31, 2027 | -$0.99 | -$1.25 to -$0.74 | 10 | $576920 | N/A | 13 |
Quarterly Estimates
The EPS consensus falls from -$0.21 for the quarter ending Dec 31, 2026 to -$0.23 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.21 | -$0.25 to -$0.19 | 18 |
| Mar 31, 2027 | -$0.23 | -$0.28 to -$0.20 | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 6 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 3 | 2 |
| Quarter ending Mar 31, 2027 | 3 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.78.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.75 | -$0.78 | -$0.78 | -$0.78 | -$0.78 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.99 | -$1.01 | -$1.00 | -$1.00 | -$1.06 | N/A |
| Quarter ending Mar 31, 2027 | -$0.23 | -$0.23 | -$0.23 | -$0.23 | -$0.23 | N/A |
Frequently Asked Questions About CLYM
What is the CLYM stock forecast?
Consensus analyst estimates put Climb Bio's EPS at -$0.75 for the fiscal year ending Dec 31, 2026. The consensus rating from 16 analysts is Buy.
How do analysts rate CLYM stock?
Of 16 analysts covering Climb Bio, 2 rate it Strong Buy, 14 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CLYM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.75, with estimates from -$0.77 to -$0.74 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.99, with estimates from -$1.25 to -$0.74 from 10 analysts.
What revenue do analysts expect from Climb Bio next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $576920.
How many analysts cover CLYM?
16 analysts rate Climb Bio stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CLYM pages: Overview, Earnings, Forecast, Financials, Competitors